Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of acute ST-segment elevation myocardial infarction

Matthias Schwenkglenks, Toby J Toward, Stephanie Plent, Thomas D Szucs, Daniel J Blackman, Andreas Baumbach

Research output: Contribution to journalArticle (Academic Journal)peer-review

24 Citations (Scopus)

Abstract

To assess the cost-effectiveness of bivalirudin versus heparin and glycoprotein IIb/IIIa inhibitor (H-GPI) in patients undergoing primary percutaneous coronary intervention (PPCI) for acute ST-segment elevation myocardial infarction (STEMI), from a UK health service perspective.
Original languageEnglish
Pages (from-to)544-51
Number of pages8
JournalHeart
Volume98
DOIs
Publication statusPublished - 2012

Keywords

  • Aged
  • Anticoagulants
  • Cost-Benefit Analysis
  • Drug Therapy, Combination
  • Electrocardiography
  • Female
  • Follow-Up Studies
  • Heparin
  • Hirudins
  • Humans
  • Male
  • Middle Aged
  • Myocardial Infarction
  • Peptide Fragments
  • Platelet Glycoprotein GPIIb-IIIa Complex
  • Quality-Adjusted Life Years
  • Recombinant Proteins
  • Retrospective Studies
  • Time Factors
  • Treatment Outcome

Fingerprint Dive into the research topics of 'Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of acute ST-segment elevation myocardial infarction'. Together they form a unique fingerprint.

Cite this